cjc1295 ipamorelin fda approval status safety Photos by Prof. Patrick J. Treacy (@ptreacy) · April 17, 2026 CJC-1295 Ipamorelin FDA Status: 2026
Description
Both compounds vie for GHS-R1a occupancy, neither achieves full receptor activation, and somatostatin feedback kicks in earlier than it would with single-compound protocols
Some peptides specifically target the growth and protection of nerve cells
Regular treatments are necessary to maintain results, and while effective for superficial pigmentation, microdermabrasion may not deliver satisfactory outcomes for deeper discolouration
CA: Cancer J
